Австралія - англійська - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 12.5 mg - oral liquid, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections - cafnea oral solution is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 20 mg - injection, intravenous infusion - excipient ingredients: sodium citrate dihydrate; water for injections; citric acid monohydrate - cafnea injection is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Мальта - англійська - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - caffeine citrate - oral solution - caffeine citrate 10 mg/ml - psychoanaleptics

Кенія - англійська - Pharmacy and Poisons Board

macarthy laboratories ltd t/a martindale pharma bamptom road harold hill romford essex rm3 8ug - caffeine citrate - solution for injection - 10mg/ml - caffeine

Кенія - англійська - Pharmacy and Poisons Board

caffeine citrate - oral drops - 20mg/ml - caffeine

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - aspirin; caffeine - film-coated tablet - 325/15 milligram(s) - salicylic acid and derivatives; acetylsalicylic acid, combinations excl. psycholeptics

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

fit-bioceuticals limited - caffeine,ribose,ubidecarenone -

США - англійська - NLM (National Library of Medicine)

eon labs, inc. - quinidine sulfate (unii: j13s2394he) (quinidine - unii:itx08688jl) - quinidine sulfate 200 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine sulfate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgement of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. the increased risk of death should specifically be considered. quinidine sulfate should be used only after alternative measures (e.g.,

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - aspirin; caffeine - film-coated tablet - 325/15 milligram(s) - salicylic acid and derivatives; acetylsalicylic acid, combinations excl. psycholeptics

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

galpharm healthcare limited - caffeine; paracetamol - tablet - 500/65 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics